Skip to content

The Effect of Wenyang Huazhuo Formula on Pregnancy Outcome of Patients with Repeated Implantation Failure

The Effect of Wenyang Huazhuo Formula on Pregnancy Outcome of Patients with Repeated Implantation Failure

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079397
Enrollment
Unknown
Registered
2024-01-02
Start date
2024-01-10
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Implantation Failure

Interventions

treatment group:Wen-Yang-Hua-Zhuo recipe
contral group:placebo

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Married women, aged 25-40; 2. It meets the diagnostic criteria of repeated planting failure; 3. There are D3 day high-quality frozen embryos that can be transplanted (the number of embryonic cells on the third day after fertilization is 7-9, the fraction of fragments is less than 10%, with stage specific cell size, and no multinucleate) or frozen blastocysts (= 3BB); 4. During the period of estrogen and progesterone replacement therapy, the intimal thickness on the day of intimal transformation was = 7 mm; 5. Volunteer and agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients preparing for PGD; 2. Egg donor; 3. Chromosome abnormalities of both or one spouse (excluding chromosome polymorphism); 4. Patients with implantation failure due to embryonic factors; 5. Uterine diseases that may affect implantation (including uterine malformation, uterine tuberculosis, uterine cavity adhesion history, submucous myoma, adenomyosis,>4 cm uterine intramural myoma); 6. Repeated spontaneous abortion (fetal loss before 28 weeks of pregnancy in the past = 2 times); 7. Those with other endocrine diseases, such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, etc., whose hormone levels have not been well controlled in the past three months; 8. Definitely diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc; 9. Untreated patients with hydrosalpinx; 10. People who are allergic to the drugs in this study.

Design outcomes

Primary

MeasureTime frame
live birth rate;

Secondary

MeasureTime frame
Continuous pregnancy rate;Clinical pregnancy rate;Biochemical pregnancy rate;

Countries

China

Contacts

Public ContactTian Xia

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

xiatian76@163.com+86 22 2798 7335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026